Psychiatric Times.
No. 4
Breast Cancer: What Psychiatrists Need to Know
By Michelle Riba, MD, MS |
April 1, 2006
Cancer treatment demands much of
patients. It is important for them to exercise
and modify certain behaviors, by
staying slim, quitting smoking, minimizing alcohol(Drug information on alcohol) intake, and decreasing
stress. They must adhere to difficult treatment
regimens, endure pain (especially
when there are bone metastases), tolerate
changes in their work and home lives,
undergo modifications in their sexual
relationships, and manage anger from
partners and children whose needs are
not met. The role of the psychiatrist is
to diagnose and treat psychiatric symptoms
and disorders and provide appropriate
psychotherapy, which might
include support, cognitive-behavioral
therapy, interpersonal therapy, couples
and family work, and group therapy.
Coordination of care may also be crucial,
especially at times of transition, such as
the transition from active treatment to
palliative or hospice care.
Psychiatric interventions
Psychotherapy can, of course, be
provided at various stages of the illness.
With any patient, making an accurate
diagnosis is essential. Within that framework,
the psychiatrist can then help the
patient with the treatment and medical
issues. Some therapies focus on enhancing
morale, and others help the patient
search for meaning29 or dignity at the end
of life.30 Therapy can be supportive or
focused on cognitive-behavioral techniques
to reduce intrusive thoughts and
behavior, such as checking and feeling
for cancer recurrence.
Not all patients request or accept
counseling, and pushing for acceptance
might not be in the patient's best interest.
Psychoeducational groups, group
psychotherapy, and support groups have
all proved helpful for some patients.
Whether such groups help patients live
longer is unclear. The data to date have
been inconclusive or not yet replicated.31,32 Having a meeting with
husbands or significant others and children
can also be quite useful to the
patient, as well as to family members.
The selective serotonin reuptake
inhibitors are the first antidepressants
prescribed since they have few side
effects and few drug interactions. Mirtazapine(Drug information on mirtazapine) (Remeron) tends to cause
weight gain, and women who are already
gaining weight because of corticosteroid
therapy or chemotherapy may be unwilling
to take it. Mirtazapine is a good agent
for cachectic patients who have lost
weight and need help with sleep.
Venlafaxine (Effexor) and paroxetine(Drug information on paroxetine)
(Paxil) have been used for women who
have hot flashes after chemotherapy or after discontinuing hormone replacement
therapy.12,33
Bupropion (Wellbutrin) is useful in
lethargic patients (but one needs to
monitor for seizures and brain tumors),
and in patients who are not eating
because of cachexia. The tricyclic antidepressants,
especially nortriptyline(Drug information on nortriptyline) and
desipramine, can be helpful in patients
who have neuropathic pain. Psychostimulants
are effective as adjuvant
treatments for depression. They decrease
fatigue and counteract opioidinduced
sedation, particularly in
terminally ill patients. In patients with
bipolar disorder, mood stabilizers and
neuroleptics can be continued during
cancer treatment. Levels of lithium(Drug information on lithium) must
be carefully monitored, especially if
there are complications from chemotherapy,
such as nausea, vomiting, and
diarrhea. For patients who have anxiety
that is not a primary manifestation
of depression, benzodiazepines are
frequently used in the acute setting, such
as when patients need to have MRI scans
or other tests, as well as during
chemotherapy. Patients often need sleep
aids to counter the side effects of corticosteroids,
chemotherapy agents, and
intrusive thoughts and nightmares.
Bupropion (Wellbutrin) is useful in
lethargic patients (but one needs to
monitor for seizures and brain tumors),
and in patients who are not eating
because of cachexia. The tricyclic antidepressants,
especially nortriptyline and
desipramine, can be helpful in patients
who have neuropathic pain. Psychostimulants
are effective as adjuvant
treatments for depression. They decrease
fatigue and counteract opioidinduced
sedation, particularly in
terminally ill patients. In patients with
bipolar disorder, mood stabilizers and
neuroleptics can be continued during
cancer treatment. Levels of lithium must
be carefully monitored, especially if
there are complications from chemotherapy,
such as nausea, vomiting, and
diarrhea. For patients who have anxiety
that is not a primary manifestation
of depression, benzodiazepines are
frequently used in the acute setting, such
as when patients need to have MRI scans
or other tests, as well as during
chemotherapy. Patients often need sleep
aids to counter the side effects of corticosteroids,
chemotherapy agents, and
intrusive thoughts and nightmares.
The advent of newer therapies and
a better understanding of the underlying
biology of breast cancer make this
a more hopeful time in breast cancer
research. Patients have more options
and choices to make in their treatment.
At the same time, the psychological
challenges of getting and living with
breast cancer remain difficult, and
many patients and their families need
help in managing psychiatric symptoms
and disorders. Our oncology
colleagues are grateful to psychiatrists
who want to work as part of the multidisciplinary
teams who take care of
patients with breast cancer during the
acute and survivorship phases of this
disease.
Dr Riba is director of the psycho-oncology
program at the University of Michigan, in Ann
Arbor Comprehensive Cancer Center and professor
and associate chair for Integrated
Medicine and Psychiatric Services in the department
of psychiatry at the University of
Michigan. She has been a consultant for Eli
Lilly, Pfizer, and GlaxoSmithKline.
References
1. Morrell RM, Halyard MY, Schild SE, et al. Breast
cancer-related lymphedema. Mayo Clin Proc.
2005;80:1480-1484.
2. American Cancer Society. Estimated new cancer
cases for selected cancer sites by state, US, 2005.
In: Cancer Fact and Figures. 2005. Available at:
www.cancer.org/docroot/MED/content/dowloads/M
ED_1_1x_CFF2005_Estimated _New_Cases_
Sites_by_State,asp. Accessed February 23, 2006.
3. American Cancer Society. Estimated new cancer
deaths for selected cancer sites by state, US, 2005.
In: Cancer Fact and Figures. 2005. Available at:
www.cancer.org/docroot/MED/content/dowloads/M
ED_1_1x_CFF2005_Estimated _Death_Sites_
by_State,asp. Accessed February 23, 2006.
4. Phillips KA. Current perspectives on BRCA1- and
BRCA2-associated breast cancers. Intern Med J.
2001;31:349-356.
5. Peshkin BN, Isaacs C. Evaluation and management
of women with BRCA1/2 mutations. Oncology
(Williston Park). 2005;19:1451-1468.
6. King MC, Rowell S, Love SM. Inherited breast
and ovarian cancer. What are the risks? What are
the choices? JAMA. 1993;269:1975-1980.
7. Hall JM, Lee MK, Newman B, et al. Linkage of
early-onset familial breast cancer to chromosome
17q21. Science. 1990;250:1684-1689.
8. Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994
and beyond. Nat Rev Cancer. 2004;4:665-676.
9. Podnos YD, Wagman LD. Surgical management
of hepatic breast cancer metastases. Oncology
(Williston Park). 2005;19:1583-1588.
10. Jardines L, Callans LS, Torosian MH. Recurrent
breast cancer: presentation, diagnosis, and treatment.
Semin Oncol. 1993;20:538-547.
11. Esteva FJ, Pusztai L. Optimizing outcomes in
HER2-positive breast cancer: the molecular rationale.
Oncology (Williston Park). 2005;19(suppl):5-16.
12. Duffy LS, Greenberg DB, Younger J, Ferraro MG.
Iatrogenic acute estrogen deficiency and psychiatric
syndromes in breast cancer patients. Psychosomatics.
1999;40:304-308.
13. Massie MJ, Greenberg DB. Oncology. In:
Levenson JL, ed. American Psychiatric Publishing
Textbook of Psychosomatic Medicine. Arlington, Va:
American Psychiatric Press; 2005:517-534.
14. Rowland JR, Massie MJ. Psychosocial issues
and interventions. In: Harris JR, Lippman ME,
Morrow M, et al, eds. Diseases of the Breast. 3rd
ed. Philadelphia: Lippincott Williams & Wilkins;
2004:1419-1452.
15. Harlan LC, Abrams J, Warren JL, et al. Adjuvant
therapy for breast cancer: practice patterns of
community physicians. J Clin Oncol. 2002;20:
1809-1817.
16. Miller SL, Jones LE, Carney CP. Psychiatric sequelae
following breast cancer chemotherapy: a pilot
study using claims data. Psychosomatics.
2005;46:517-522.
17. Irvine D, Brown B, Crooks D, et al. Psychosocial
adjustment in women with breast cancer. Cancer.
1991;67:1097-1117.
18. Maguire P. Psychosocial interventions to reduce
affective disorders in cancer patients: research priorities.
Psychooncology. 1995;4:113-119.
19. Hann D, Winter K, Jacobsen P. Measurement of
depressive symptoms in cancer patients: evaluation
of the Center for Epidemiological Studies Depression
Scale (CES-D). J Psychosom Res. 1999;46:437-443.
20. Baider L, Kaplan De-Nour A. Psychological
distress and intrusive thoughts in cancer patients.
J Nerv Ment Dis. 1997;185:346-348.
21. Massie MJ. Prevalence of depression in patients with
cancer. J Natl Cancer Inst Monogr. 2004;57-71.
22. Polsky D, Doshi JA, Marcus S, et al. Long-term
risk for depressive symptoms after a medical diagnosis.
Arch Intern Med. 2005;165:1260-1266.
23. National Comprehensive Cancer Network.
Distress management. Practice guidelines in oncology-
v.1.2005. Available at: www.nccn.org. Accessed
February 23, 2006.
24. Kerlikowske K, Grady D, Rubin SM, et al. Efficacy
of screening mammography. A meta-analysis.
JAMA.1995;273:149-154.
25. Brett J, Bankhead C, Henderson B, et al. The psychological
impact of mammographic screening. a systematic
review. Psychooncology. 2005;14:917-938.
26. Pharoah PD, Day NE, Duffy S, et al. Family history
and the risk of breast cancer. a systematic review
and meta-analysis. Int J Cancer. 1997;5:800-809.
27. Lloyd S, Watson M, Waites B, et al. Familial
breast cancer: a controlled study of risk perception,
psychological morbidity and health beliefs in women
attending for genetic counselling. Br J Cancer. 1996;
74:482-487.
28. Zakowski SG, Valdimarsdottir HB, Bovbjerg DH,
et al. Predictors of intrusive thoughts and avoidance
in women with family histories of breast cancer.
Am Behav Med. 1997;19:362-369.
29. Greenstein M, Breitbart W. Cancer and the experience
of meaning: a group psychotherapy program
for people with cancer. Am J Psychother. 2000;
54:486-500.
30. Chochinov HM. Dignity-conserving care—a new
model for palliative care: helping the patient feel
valued. JAMA. 2002;287:2253-2260.
31. Goodwin PJ, Leszcz M, Ennis M, et al. The effect
of group psychosocial support on survival in metastatic
breast cancer. N Engl J Med. 2001;345:1719-1726.
32. Spiegel D, Bloom JR, Kramer HC, Gottheil E.
Effect of psychosocial treatment on survival of
patients with metastatic breast cancer. Lancet.
1989;2:888-891.
33. Stearns V, Isaacs C, Rowland J, et al. A pilot
trial assessing the efficacy of paroxetine hydrochloride
(Paxil) in controlling hot flashes in breast cancer
survivors. Ann Oncol. 2000;11:17-22.
|
Five Steps to Improving Patient Access Judy Capko, May 21, 2013 Patient access is getting increased attention through reform initiatives. Here are five steps you can take to make sure patients get appropriate access to care in your office.
SearchMedica SEARCH RESULT
Find peer-reviewed literature and websites for practicing medical professionals
|